company background image
IOT

Innovotech TSXV:IOT Stock Report

Last Price

CA$0.15

Market Cap

CA$5.8m

7D

-11.8%

1Y

11.1%

Updated

21 May, 2022

Data

Company Financials
IOT fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance5/6
Financial Health6/6
Dividends0/6

IOT Stock Overview

Innovotech Inc. provides solutions to medical, agricultural, and industrial problems caused by microbial biofilms in Canada, the United States, and internationally.

Innovotech Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Innovotech
Historical stock prices
Current Share PriceCA$0.15
52 Week HighCA$0.23
52 Week LowCA$0.12
Beta1.3
1 Month Change-25.00%
3 Month Change-25.00%
1 Year Change11.11%
3 Year Change130.77%
5 Year Change100.00%
Change since IPO-28.57%

Recent News & Updates

Mar 02
Would Financials Be Able To Push Innovotech Inc.'s (CVE:IOT) Stock Prices Higher In The Near Future?

Would Financials Be Able To Push Innovotech Inc.'s (CVE:IOT) Stock Prices Higher In The Near Future?

Looking at Innovotech's (CVE:IOT) mostly flat share price movement over the past week, it is easy to think that there’s...

Shareholder Returns

IOTCA Life SciencesCA Market
7D-11.8%11.6%0.8%
1Y11.1%-8.5%4.8%

Return vs Industry: IOT exceeded the Canadian Life Sciences industry which returned -9.5% over the past year.

Return vs Market: IOT exceeded the Canadian Market which returned 4.6% over the past year.

Price Volatility

Is IOT's price volatile compared to industry and market?
IOT volatility
IOT Average Weekly Movementn/a
Life Sciences Industry Average Movement10.8%
Market Average Movement9.9%
10% most volatile stocks in CA Market16.9%
10% least volatile stocks in CA Market4.4%

Stable Share Price: Insufficient data to determine IOT's volatility over the past 3 months.

Volatility Over Time: Insufficient data to determine IOT's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2001n/aJames Timourianhttps://www.innovotech.ca

Innovotech Inc. provides solutions to medical, agricultural, and industrial problems caused by microbial biofilms in Canada, the United States, and internationally. The company offers InnovoSIL, an antimicrobial agents for coating onto or incorporation into medical devices; MBEC Assay, a screening assay used to determine the efficacy of antimicrobials against biofilms of various microorganisms; and AgreGuard, an antimicrobial for crop protection. It also provides implant medical devices; antibiotic, antimicrobial, and biocide resistance; biofilm eradication surface and MBEC Assay testing; and analytical services.

Innovotech Fundamentals Summary

How do Innovotech's earnings and revenue compare to its market cap?
IOT fundamental statistics
Market CapCA$5.84m
Earnings (TTM)CA$367.13k
Revenue (TTM)CA$1.48m

15.9x

P/E Ratio

3.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
IOT income statement (TTM)
RevenueCA$1.48m
Cost of RevenueCA$363.15k
Gross ProfitCA$1.12m
Other ExpensesCA$751.48k
EarningsCA$367.13k

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.0094
Gross Margin75.49%
Net Profit Margin24.78%
Debt/Equity Ratio0%

How did IOT perform over the long term?

See historical performance and comparison

Valuation

Is Innovotech undervalued compared to its fair value and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


15.91x

Price to Earnings (PE) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate IOT's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate IOT's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: IOT is good value based on its PE Ratio (15.9x) compared to the North American Life Sciences industry average (31.3x).

PE vs Market: IOT is poor value based on its PE Ratio (15.9x) compared to the Canadian market (11.5x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IOT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IOT is overvalued based on its PB Ratio (5x) compared to the XN Life Sciences industry average (2.5x).


Future Growth

How is Innovotech forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


12.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Innovotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Innovotech performed over the past 5 years?

Past Performance Score

5/6

Past Performance Score 5/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


1.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: IOT has a high level of non-cash earnings.

Growing Profit Margin: IOT's current net profit margins (24.8%) are higher than last year (8.9%).


Past Earnings Growth Analysis

Earnings Trend: IOT has become profitable over the past 5 years, growing earnings by 1.9% per year.

Accelerating Growth: IOT's earnings growth over the past year (245.3%) exceeds its 5-year average (1.9% per year).

Earnings vs Industry: IOT earnings growth over the past year (245.3%) exceeded the Life Sciences industry 21.7%.


Return on Equity

High ROE: IOT's Return on Equity (31.2%) is considered high.


Financial Health

How is Innovotech's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: IOT's short term assets (CA$993.5K) exceed its short term liabilities (CA$219.0K).

Long Term Liabilities: IOT's short term assets (CA$993.5K) exceed its long term liabilities (CA$37.0K).


Debt to Equity History and Analysis

Debt Level: IOT is debt free.

Reducing Debt: IOT currently has no debt however we can't compare to 5 years ago as we have no data for that period.

Debt Coverage: IOT has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: IOT has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Innovotech current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate IOT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IOT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IOT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IOT's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as IOT has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.4yrs

Average management tenure


CEO

James Timourian

8.33yrs

Tenure

CA$13,500

Compensation

Dr. James Timourian, Ph.D. has been the President of Innovotech Inc. since January 01, 2014 and serves as its Chief Executive Officer and Secretary. Dr. Timourian has been Mathematician, President of Integ...


Leadership Team

Experienced Management: IOT's management team is considered experienced (2.4 years average tenure).


Board Members

Experienced Board: IOT's board of directors are considered experienced (5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Innovotech Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Innovotech Inc.
  • Ticker: IOT
  • Exchange: TSXV
  • Founded: 2001
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: CA$5.836m
  • Shares outstanding: 38.91m
  • Website: https://www.innovotech.ca

Location

  • Innovotech Inc.
  • 2011-94 Street
  • Suite L131
  • Edmonton
  • Alberta
  • T6N 1H1
  • Canada

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/21 00:00
End of Day Share Price2022/05/20 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.